Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight
Cervical Cancer Market is Expected
to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM:
DelveInsight
LAS VEGAS, US (DelveInsight)-- The coming
decade is expected to witness a rise in targeted therapies in the pipeline and
a better drug delivery approach that shall give the cervical cancer market a boost. An increase in
cervical cancer incidence is also a major reason behind the accelerated
momentum of the cervical cancer market size growth. Further, increased
healthcare spending, better diagnosis, and heightened R&D to facilitate a
better understanding and increased awareness of the disease are some other
driving factors.
View report: https://www.delveinsight.com/report-store/cervical-cancer-market
Some of the key insights from cervical cancer market report:
- The
incidence of cervical cancer in 7MM (US,
UK, Germany, Italy, Spain, France & Japan)
in 2020 is expected to be 43,712.
- In
the 7MM, the USA is the major contributor to the cervical cancer
market revenue in 2020, and the region is expected to hold its position in
the upcoming years.
- Key
companies propelling the market size include Regeneron, AstraZeneca,
Lovance, Zeria Pharmaceutical, Seattle Genetics/Genmab, Agenus Bio, Roche,
Akeso Biopharma and Vaccibody/Roche, among others.
- Launch
of cervical cancer pipeline therapies, including Cemiplimab (Regeneron),
Durvalumab (AstraZeneca), LN-145 (Iovance), Z-100 (Zeria Pharmaceutical),
Tisotumab vedotin (Seattle Genetics/Genmab) in the next decade is expected
to propel the market growth.
Get a cervical cancer sample copy or download a cervical
cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
View report: https://www.delveinsight.com/report-store/cervical-cancer-market
Cervical cancer is a cause of infection from Human
papillomavirus (HPV), which can be prevented. Due to its slow progression, the
precancerous cells can be detected through proper screening with a Pap smear
test and HPV test; and can be prevented through HPV vaccination (Cervarix and
Gardasil 9). However, a lack of awareness and misconceptions hinder screening
and its early diagnosis.
DelveInsight estimated that cervical cancer is most often
diagnosed in women between the ages of 35 and 44, with the average age at
diagnosis being 50. The late diagnosis in women is a consequence of a lack of
vaccination and screening in women in the early stages of their lives.
For cancer, which is preventable in the first place, the
mortality rate due to advanced cervical cancer is relatively high. However, the
rate varies with the different stages of cancer, geographies, ethnicities, and
age-groups.
To know more about Cervical Cancer Incidence, Diagnosis
and Mortality Visit: https://www.delveinsight.com/report-store/cervical-cancer-market
View report: https://www.delveinsight.com/report-store/cervical-cancer-market
The cervical cancer epidemiology section in the
report provides historical and forecasted analysis upto 2030 segmented
by:
- Incident
cases of Cervical Cancer
- Stage-specific
Incidence of Cervical Cancer
- Histopathologic
Types of Cervical Cancer
- Age-specific
causes of Cervical Cancer
The present treatment market for cervical cancer is mainly
bifurcated into therapeutics and preventive. The preventive cervical cancer
treatment market comprises two candidates, namely Cervarix (Merck) and Gardasil
(GlaxoSmithKline).
For advanced, metastatic cervical cancer, the available
treatments in the market constitute traditional chemotherapies, targeted
monoclonal antibodies, biosimilars, and immunotherapies. Targeted therapies
such as Avastin have revolutionized the treatment landscape
for cervical cancer, which are often given in combination with chemotherapy.
Avastin has enjoyed market exclusivity and has been a top-earner of Roche.
However, after its patent expiry in 2019 in the US, it faced rigorous
competition from Amgen's Mvasi, Pfizer's Zirabev, and
Samsung's Aybintio. The sales of the therapy have declined in the
US due to the approvals of copycats, which are priced considerably lower than
the original one. The sales of the drug will decline in the European market in January
2022 due to a similar fate.
View report: https://www.delveinsight.com/report-store/cervical-cancer-market
The cervical cancer market also homes Merck's star, Keytruda,
which got approval in 2018 for advanced cervical cancer for PD-L1 positive
patients. Keytruda is the only approved immunotherapy in the cervical cancer
market landscape; hence it enjoys the monopoly in the domain. However, sooner
it will be vying for dominance as Regeneron and Sanofi's contender Libtayo is
proceeding towards the finish line. Furthermore, to minimize the effect of
inevitable patent expiry, Merck is testing a combination of Keytruda with
Chemoradiotherapy for patients with high-risk locally advanced cervical cancer
(NCT04221945). Enrolment is ongoing for Phase III, and the study is expected to
be completed by the end of 2024.
Recently, at ASCO 2020, Genmab demonstrated the positive
benefit-to-risk profile of its drug Tisotumab vedotin, a first-in-class
antibody-drug conjugate directed against tissue factor (TF). Now the company
plans to investigate the drug in combination with other cancer drugs, namely
Bevacizumab, Pembrolizumab, and Carboplatin in a Phase Ib/II trial to find out
the correct dosage in recurrent or metastatic cervical cancer
(NCT03786081).
The Cervical cancer market has several treatment drugs in
the late-stage as well as early phase of development in the pipeline. The
expected launch of pipeline therapies in the foreseeable future shall
significantly impact the Cervical cancer market. A better understanding of the
HPV and its interaction with the host has given rich insights into the
therapeutic domain.
Further, the launch of prophylactic as well as therapeutic
vaccines, will transform the cervical cancer treatment landscape. Prophylactic
cancer vaccines have been successful in dampening the disease burden; however,
they cannot help the patients with established tumors, which Scientists believe
can be tackled by the use of therapeutic vaccines. However, the neoantigens
that are the basis of the therapeutic cancer vaccine are unique to patients
thus, it requires the development of personalized therapies. Among all the
candidates in the distant pipeline, only one to reach Phase III is VGX-3100, a
candidate of Inovio Pharmaceuticals.
Also, research is underway to identify therapeutic targets
and develop curative therapy to treat cervical cancer. Scientists are
investigating the potential of biomarkers among cervical cancer patients that
shall define the screening and diagnosis of cancer to a greater extent. A
combination of multiple potential biomarkers, including serum proteins,
microRNAs, ctDNA mutations, and others, can significantly increase the
sensitivity of the screening and detection of cervical cancers.
View report: https://www.delveinsight.com/report-store/cervical-cancer-market
Although cervical cancer market growth may face obstructions
in the face of lack of awareness among common people, delayed diagnosis, high
cost of treatment, and palliative treatment options for metastatic cancer.
Nevertheless, the renewed interest in targeted therapies, personalized
medicine, and rising R&D that has facilitated the identification of
actionable biomarkers offer a promising and flourishing environment to the
global cervical cancer market.
Scope of the Report
- Geography
Covered: 7MM - The United States, EU5
(Germany, France, Italy, Spain, and the United
Kingdom), Japan.
- Study
Period: 3-year historical and 11-year forecasted analysis
(2017-2030).
- Markets
Segmentation: By Geographies, By Therapies (Forecasted + Historical).
- Companies
Covered: Regeneron, AstraZeneca, Iovance, Zeria Pharmaceutical,
Seattle Genetics/Genmab, Agenus Bio, Roche, Akeso Biopharma, and
Vaccibody/Roche among others.
- Analysis:
Comparative and conjoint analysis of emerging therapies, Attribute
Analysis,
- Case
Studies
- KOL's
Views
- Analyst's
View
Request for Webex demo: https://www.delveinsight.com/report-store/cervical-cancer-market
Table of Contents
|
1 |
Key Insights |
|
2 |
Executive Summary of Cervical Cancer |
|
3 |
SWOT Analysis of Cervical Cancer |
|
4 |
Cervical Cancer Epidemiology Overview at a Glance |
|
5 |
Cervical Cancer Market Overview at a Glance |
|
6 |
Disease Background and Overview: Cervical Cancer |
|
7 |
Epidemiology and Patient Population |
|
8 |
Country Wise-Epidemiology of Cervical Cancer |
|
9 |
Cervical Cancer Treatment and Management |
|
10 |
Unmet Needs in the Cervical Cancer Market |
|
11 |
Cervical Cancer Marketed Therapies |
|
12 |
Cervical Cancer Emerging Therapies |
|
13 |
Cervical Cancer: Other Promising Therapies |
|
14 |
Cervical Cancer 7 Major Market Analysis |
|
15 |
7MM Cervical Cancer Country-Wise Analysis |
|
16 |
Cervical Cancer Market Drivers |
|
17 |
Cervical Cancer Market Barriers |
|
18 |
Appendix |
|
19 |
DelveInsight Capabilities |
|
20 |
Disclaimer |
|
21 |
About DelveInsight |
*The TOC is illustrative, request for a detailed TOC.
Related Report
Cervical Intraepithelial Neoplasia Market Insight, Epidemiology
and Market Forecast -2030
Cervical Intraepithelial Neoplasia (CIN) or cervical dysplasia
is a precancerous condition characterized by an unusual growth of the cells on
the surface lining of the cervix or endocervical canal.
The report proffers a detailed section of the indication
overview, signs symptoms, with a major focus on CIN epidemiology in the 7MM,
present treatment modalities, and emerging therapies in the pipeline. The
report lays down an in-depth understanding of the market landscape, key
collaborations, partnerships, R&D development, and driving forces as well
as restrains in the market growth.
Human Papillomavirus virus (HPV) is a cause of a significant
burden on global healthcare. HPV infections, if neglected, can results in
several diseases, including anogenital warts and recurrent respiratory
papillomatosis and several forms of cancers.
The report provides rich insights into the indication, its
etiology, pathogenesis, manifestation with an exclusive focus on historical as
well as forecasted epidemiology and market trends. The report brings a
comprehensive analysis of the market landscape, recent happenings,
breakthroughs, key partnerships, present and emerging treatments, market
barriers, and drivers.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports Pharma
companies by providing end to end comprehensive solutions to improve their
performance. Get hassle-free access to all the healthcare and pharma
market research reports through our subscription-based platform PharmDelve.
Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
Comments
Post a Comment